Results 81 to 90 of about 54,075 (219)
Asia-Pacific Journal of Clinical Oncology, EarlyView.This study investigated the real‐world use of CDK4/6 inhibitors in Australian patients with HR+/HER2‐ advanced or metastatic breast cancer, providing data on patient demographics, treatment patterns, and outcomes with palbociclib. ABSTRACT Background There is limited real‐world data on the use of CDK4/6 inhibitors in Australian patients with HR+/HER2 ...
Louise Nott +8 more
wiley +1 more source
eLifeTrastuzumab resistance remains a challenge for HER2-positive breast cancer treatment. Targeting metabolic reprogramming would provide novel insights for therapeutic strategies.
Yijia Hua +13 more
doaj +1 more source
ANZ Journal of Surgery, EarlyView.ABSTRACT Background Neoadjuvant systemic therapy (NAST) induces morphological changes within the axilla; however, its impact on lymph node yield (LNY) following axillary lymph node dissection (ALND) is less clear. Methods A retrospective cohort study was performed including female patients who underwent ALND for biopsy‐proven node‐positive breast ...
Zachary Pluim +4 more
wiley +1 more source
Alimentary Pharmacology &Therapeutics, EarlyView.In ANA‐positive patients with suspected autoimmune hepatitis (AIH), liver biopsy rarely altered therapeutic management when alanine aminotransferase (ALT) was below 101 U/L and cirrhosis was absent. These findings suggest that biopsy may be safely deferred in this low‐risk group.
David Mehdi Asgher Niazi +8 more
wiley +1 more source
British Journal of Pharmacology, EarlyView.Background and Purpose Musclin (osteocrin) is a skeletal muscle‐derived peptide that has been implicated in cardioprotective signalling pathways. Its relevance in cancer patients, who frequently experience muscle wasting and cardiotoxicity, remains unclear. This study aimed to determine whether circulating Musclin levels reflect functional capacity and
Jannek Brauer +5 more
wiley +1 more source
مجله دانشگاه علوم پزشکی بیرجند, 2017 Background and Aim: Resistance to trastuzumab has been a critical barrier to targeted therapy of HER 2-positive (Human Epidermal Growth Factor Receptor 2) breast cancers.
Zohreh Rezaei +3 more
doaj
Cancer Science, EarlyView.Graphical representation of formation of self‐assembled PEGylated Chitosan Nanoparticles and their mechanism in tumor localization. ABSTRACT Polymer‐based nanocarriers have emerged as transformative platforms in cancer nanomedicine, enabling controlled and site‐specific delivery of therapeutic agents.
Prashant Kesharwani +5 more
wiley +1 more source
Cancer Science, EarlyView.The CD90‐YY1‐SLC1A5 axis plays a significant role in gastric cancer. CD90 promotes the binding of YY1 to the SLC1A5 promoter. CD90 regulates SLC1A5‐mediated glutamine metabolism and ferroptosis. ABSTRACT CD90 (THY1) is a cell surface glycoprotein that plays a crucial role in the occurrence and development of various malignant tumors.
Zihua Zhou +5 more
wiley +1 more source
The FEBS Journal, EarlyView.The extracellular matrix (ECM) is a dynamic scaffold that orchestrates tissue architecture and cellular communication. A critical but underexplored interplay between proteases and cluster of differentiation molecules (CD) governs ECM turnover and directs cell fate.
David Jurnečka +3 more
wiley +1 more source
World Health Organization classification of tumours of the breast 6th edition 2026
Histopathology, EarlyView.The 6th edition of the World Health Organization Classification of Breast Tumours introduces changes based on recent advances in our understanding of breast biology, developments in diagnostic modalities, identification of specific molecular targets and new treatment regimes.
Cecily Quinn +47 more
wiley +1 more source